|1.||Wei, Qingyi: 4 articles (11/2008 - 09/2002)|
|2.||Tang, Wenru: 3 articles (01/2015 - 06/2012)|
|3.||Xu, Wei: 3 articles (04/2014 - 05/2009)|
|4.||Mahanta, Jagadish: 3 articles (01/2014 - 03/2011)|
|5.||Christiani, David C: 3 articles (09/2013 - 01/2003)|
|6.||Weiler, Hartmut: 3 articles (01/2013 - 09/2009)|
|7.||Jiang, De-Ke: 3 articles (12/2011 - 09/2010)|
|8.||Peng, Bo: 3 articles (12/2011 - 09/2010)|
|9.||Wang, Wen-Zhang: 3 articles (12/2011 - 09/2010)|
|10.||Yu, Long: 3 articles (12/2011 - 09/2010)|
11/01/2006 - "In the obese subgroup (BMI >30 kg/m(2)), fasting glucose (P = 0.041) and insulin resistance (by homeostasis model analysis) (P = 0.020) were significantly greater in the Pro/Pro group. "
07/15/2012 - "Odds ratios (ORs) and 95% confidence intervals (CIs) for Pro/Ala+Ala/Ala versus Pro/Pro genotype in all population and different nationality groups, and homeostasis model assessment-insulin resistance (HOMA-IR) of different genotype were evaluated. "
11/01/2008 - "However, insulin and homeostasis model assessment of insulin resistance levels were lower in carriers of the Pro/Pro genotype (-4.0 vs 0.7 IU/L, P=0.009 and -1.0 vs -0.08, P = 0.03, respectively). "
01/01/2007 - "The Ala allele did not show a significant effect on anthropometric and biochemical parameters in the type 2 diabetic group, whereas in non-diabetic subjects, carriers of the Ala allele had significantly lower fasting insulin (p=0.007) and homeostasis model assessment of insulin resistance (HOMA-IR) (p=0.009) levels compared to Pro/Pro subjects. "
11/01/2006 - "In the global comparison, there were no differences in BMI, glucose, insulin, or homeostasis model assessment of insulin resistance between the Pro/Pro and X/Ala genotype. "
|2.||Mouth Neoplasms (Oral Cancer)
07/01/2003 - "However, our data suggest that for individuals who were younger than 65 years old, the Pro/Pro genotype may offer some protection against oral cancer (OR = 0.13, 95%CI 0.04-1.10). "
10/01/2009 - "Similarly, individuals with a combined Arg genotype (Arg/Pro+Arg/Arg) do not have a marked increased or decreased susceptibility to oral cancer relative to those with homozygote Pro/Pro genotype (OR: 1.00, 95% CI: 0.83-1.21). "
11/01/2007 - "Our results suggest the Pro/Pro genotype of the TP53 codon72 polymorphism increases oral cancer risk in non-smokers and worsens their prognosis."
10/01/2009 - "Results showed that no significant differences of oral cancer risk were found between individuals carrying homozygote Arg/Arg genotype and those carrying Pro/Pro genotype (OR: 0.96, 95% CI: 0.78-1.19). "
11/01/2008 - "We found that HPV16 seropositivity was associated with an increased risk of oral cancer [adjusted odds ratio (OR), 3.42; 95% confidence interval (CI), 2.28-5.13], especially among never-smokers (adjusted OR, 8.20; 95% CI, 3.66-18.4) and subjects with variant genotypes [adjusted OR for p53 Arg/Pro + Pro/Pro (Pro carriers), 5.00; 95% CI, 2.72-9.21; adjusted OR for p73 GC/AT + AT/AT (AT carriers), 3.83; 95% CI, 1.98-7.41]. "
04/01/2013 - "Concurrently, genotyping of the Pro12Ala polymorphism showed that obese subjects possess a significantly higher frequency of the Pro/Pro genotype than nonobese controls (90.5 vs 79.5%; P = 0.03), suggesting that this genotype is involved in an increased risk of obesity in the Tunisian population. "
04/01/2011 - "In both cohorts, no differences were found in obesity traits between the Ala allele carriers and Pro/Pro homozygotes. "
11/01/2009 - "In comparison to Pro/Pro homozygotes, Ala-allele bearers had a significantly higher risk of obesity [OR (95% CI)=3.26 (1.28-8.33)]. "
06/01/2000 - "Among obese women, the Pro12Ala mutation lowered age of obesity onset (Pro/Pro, 13.2 +/- 9. 4 years; Pro/Ala+Ala/Ala 8.6 +/- 7.1 years, P = 0.005), was associated with lower fasting glucose and was protective against type II diabetes."
06/01/2015 - "The combined results showed that PPAR-γ Pro12Ala polymorphism was associated with the obesity risk (Ala vs. Pro: OR = 1.55, 95 % CI 1.34-1.80; Pro/Ala vs. Pro/Pro: OR = 1.54, 95 % CI 1.31-1.82; Ala/Ala + Pro/Ala vs. Pro/Pro: OR = 1.61, 95 % CI 1.36-1.90). "
10/10/2011 - "These results show that nasal drops of Pro-Pro-[Arg¹¹] hPTH (1-34)-Pro-Pro are effective against osteoporosis."
06/01/2012 - "We have previously shown that a recombinant human PTH fragment, Pro-Pro-[Arg11] hPTH (1-34)-Pro-Pro-Asp (hPTH'), could be a potentially better and more cost-effective therapeutic agent than PTH (1-34) on osteoporosis. "
12/18/2012 - "The results suggest that Pro-Pro-hPTH (1-34) has a positive effect on bone growth and strength, and possesses anti-fracture capability, thus a potential candidate for the application for the treatment of osteoporosis."
01/01/2014 - "There are divergent reports but many studies suggest p53 pro/pro SNP may be associated with susceptibility to developing various cancers in different regions of the world. "
01/01/2015 - "At the same time, there was a significant correlation between the level of lipid peroxidation and GPx1 activity among the cancer subjects possessing GPX1 Pro/Pro genotype (r = 0.3043; p = 0.0089), whereas such a correlation was completely absent in the cases carrying at least one GPX1 Leu allele as well as in the controls (regardless of GPX1 genotype). "
11/01/2014 - "Although P53c72 polymorphism does not appear to be a predisposing factor for OSCC in the population of Northern Iran, the Pro/Pro genotype could be considered as a risk factor for OSCC in adults below 50 years old and the anatomical location of the tumor."
11/01/2014 - "Interestingly, a large portion (40%) of the patients with the Pro/Pro genotype had the tumor in the lip area. "
07/01/2014 - "Here the wild-type Pro/Pro genotype at the TP53Pro72Arg (P72R) polymorphism (SNP: rs1042522) is more frequent in African Americans with cancer than in African Americans without cancer (51% vs. 37%), and is associated with a significant increase in the rates of cancer diagnosis in African Americans. "
|6.||DNA (Deoxyribonucleic Acid)
|10.||Transforming Growth Factor beta (TGF-beta)
|1.||Drug Therapy (Chemotherapy)
|2.||Photochemotherapy (Photodynamic Therapy)